Caitlin A. Colling

Endocrinology

50 Staniford St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.

Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.

Journal: American heart journal

Published: August 24, 2025

Case 8-2025: A 72-Year-Old Woman with Altered Mental Status and Acidemia.

Case 8-2025: A 72-Year-Old Woman with Altered Mental Status and Acidemia.

Journal: The New England journal of medicine

Published: March 12, 2025

Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care: A Quality Improvement Project.

Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care: A Quality Improvement Project.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: February 13, 2025

Expanding Access to Continuous Glucose Monitoring Through Empowering Primary Care: A Joint Endocrinology-Primary Care Quality Improvement Project.

Expanding Access to Continuous Glucose Monitoring Through Empowering Primary Care: A Joint Endocrinology-Primary Care Quality Improvement Project.

Journal: Journal of general internal medicine

Published: October 04, 2024

Identification of Immune Checkpoint Inhibitor-Induced Diabetes.

Identification of Immune Checkpoint Inhibitor-Induced Diabetes.

Journal: JAMA oncology

Published: August 29, 2024

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial.

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial.

Journal: American heart journal

Published: August 28, 2024

Enrollment strategies in the era of digital revolution: Experience from a remote health management program.

Enrollment strategies in the era of digital revolution: Experience from a remote health management program.

Journal: American heart journal

Published: June 21, 2024

Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.

Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.

Journal: Circulation

Published: April 07, 2024

Type 2 diabetes disease and management patterns across a large, diverse healthcare system: Issues and opportunities for guideline-directed therapies.

Type 2 diabetes disease and management patterns across a large, diverse healthcare system: Issues and opportunities for guideline-directed therapies.

Journal: American heart journal

Published: February 16, 2024

Changes in serum cortisol levels after 10 days of overfeeding and fasting.

Changes in serum cortisol levels after 10 days of overfeeding and fasting.

Journal: American journal of physiology. Endocrinology and metabolism

Published: April 13, 2023

Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk.

Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk.

Journal: Primary care diabetes

Published: March 10, 2023

Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial.

Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial.

Journal: The Journal of clinical endocrinology and metabolism

Published: March 08, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026